These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
492 related articles for article (PubMed ID: 16977285)
1. Herpes zoster vaccine (Zostavax). Med Lett Drugs Ther; 2006 Sep; 48(1243):73-4. PubMed ID: 16977285 [TBL] [Abstract][Full Text] [Related]
2. A novel vaccine (Zostavax) to prevent herpes zoster and postherpetic neuralgia. Holcomb K; Weinberg JM J Drugs Dermatol; 2006 Oct; 5(9):863-6. PubMed ID: 17039651 [TBL] [Abstract][Full Text] [Related]
3. [Study tests Varicella-Zoster vaccine for over 60-years-old persons. Protection from Herpes zoster and postherpetic neuralgia]. MMW Fortschr Med; 2006; Spec no.1():14-5. PubMed ID: 16872127 [No Abstract] [Full Text] [Related]
4. Vaccination: a new option to reduce the burden of herpes zoster. Mick G Expert Rev Vaccines; 2010 Mar; 9(3 Suppl):31-5. PubMed ID: 20192716 [TBL] [Abstract][Full Text] [Related]
7. A novel vaccine (Zostavax) to prevent herpes zoster. Holcomb K; Weinberg JM G Ital Dermatol Venereol; 2008 Apr; 143(2):119-23. PubMed ID: 18833038 [TBL] [Abstract][Full Text] [Related]
8. Zostavax : a subcutaneous vaccine for the prevention of herpes zoster. Doan HQ; Ung B; Ramirez-Fort MK; Khan F; Tyring SK Expert Opin Biol Ther; 2013 Oct; 13(10):1467-77. PubMed ID: 23984934 [TBL] [Abstract][Full Text] [Related]
9. Prevention of shingles by varicella zoster virus vaccination. Holodniy M Expert Rev Vaccines; 2006 Aug; 5(4):431-43. PubMed ID: 16989624 [TBL] [Abstract][Full Text] [Related]
10. Emerging drugs for varicella-zoster virus infections. Andrei G; Snoeck R Expert Opin Emerg Drugs; 2011 Sep; 16(3):507-35. PubMed ID: 21699441 [TBL] [Abstract][Full Text] [Related]
11. Vaccination strategies for the prevention of herpes zoster and postherpetic neuralgia. Betts RF J Am Acad Dermatol; 2007 Dec; 57(6 Suppl):S143-7. PubMed ID: 18021866 [TBL] [Abstract][Full Text] [Related]
12. Shingles vaccine: who should get it? Johnson AM S D Med; 2006 Aug; 59(8):349-50. PubMed ID: 16941852 [No Abstract] [Full Text] [Related]
13. Evaluation of the cost-effectiveness in the United States of a vaccine to prevent herpes zoster and postherpetic neuralgia in older adults. Pellissier JM; Brisson M; Levin MJ Vaccine; 2007 Nov; 25(49):8326-37. PubMed ID: 17980938 [TBL] [Abstract][Full Text] [Related]
14. Zoster vaccine (Zostavax): a review of its use in preventing herpes zoster and postherpetic neuralgia in older adults. Sanford M; Keating GM Drugs Aging; 2010 Feb; 27(2):159-76. PubMed ID: 20104941 [TBL] [Abstract][Full Text] [Related]
15. Breadth and Functionality of Varicella-Zoster Virus Glycoprotein-Specific Antibodies Identified after Zostavax Vaccination in Humans. Sullivan NL; Reuter-Monslow MA; Sei J; Durr E; Davis CW; Chang C; McCausland M; Wieland A; Krah D; Rouphael N; Mehta AK; Mulligan MJ; Pulendran B; Ahmed R; Vora KA J Virol; 2018 Jul; 92(14):. PubMed ID: 29743372 [TBL] [Abstract][Full Text] [Related]
16. Post-licensure safety surveillance of zoster vaccine live (Zostavax®) in the United States, Vaccine Adverse Event Reporting System (VAERS), 2006-2015. Miller ER; Lewis P; Shimabukuro TT; Su J; Moro P; Woo EJ; Jankosky C; Cano M Hum Vaccin Immunother; 2018; 14(8):1963-1969. PubMed ID: 29580194 [TBL] [Abstract][Full Text] [Related]
17. [Prevention of herpes zoster by vaccination]. Kofoed K; Rønholt F; Gerstoft J; Sand C Ugeskr Laeger; 2011 Jan; 173(2):110-4. PubMed ID: 21219841 [TBL] [Abstract][Full Text] [Related]